Evidence map›Paper›PMID 38116000›Full record

ReviewFrontiers in immunology2023

Mulibrey nanism and immunological complications: a comprehensive case report and literature review.

Andrea Gazzin, Francesca Pala, Marita Bosticardo, Julie Niemela, Jennifer Stoddard, Eleonora Biasin, Paola Quarello, Diana Carli, Francesca Ferroni, Ottavia M Delmonte and 4 more

Open access · goldAbstract readCase ReportsReview
In one paragraph

Review in Frontiers in immunology, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
2.1field-weighted citation impact, top 12% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed, 5 citations in OpenAlex.

  1. Mulibrey Nanism: Clinical Spectrum and Molecular Pathogenesis.International journal of molecular sciences · 2026
    Review
  2. Rediscovering the human thymus through cutting-edge technologies.The Journal of experimental medicine · 2024
    Review
  3. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

14 authors at 4 institutions in 2 countries.

Andrea GazzinLaboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, United States.
Francesca PalaLaboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, United States.
Marita BosticardoLaboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, United States.
Julie NiemelaDepartment of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United States.
Jennifer StoddardDepartment of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United States.
Eleonora BiasinPediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Paola QuarelloPediatric Onco-Hematology, Stem Cell Transplantation and Cellular Therapy Division, Regina Margherita Children's Hospital, Turin, Italy.
Diana CarliImmunogenetics and Transplant Biology Unit, Città della Salute e della Scienza University Hospital, Turin, Italy.
Francesca FerroniDepartment of Pediatric Cardiology, City of Health and Science University Hospital, Turin, Italy.
Ottavia M DelmonteLaboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, United States.
Davide MontinDepartment of Public Health and Pediatrics, University of Turin, Pediatria Specialistica U, "Regina Margherita" Children Hospital, Turin, Italy.
Sergio D RosenzweigDepartment of Laboratory Medicine, National Institutes of Health Clinical Center, Bethesda, MD, United States.
Francesco LicciardiDepartment of Public Health and Pediatric Sciences, University of Torino, Torino, Italy.
Luigi D NotarangeloLaboratory of Clinical Immunology and Microbiology, Immune Deficiency Genetics Section, National Institutes of Health, Bethesda, MD, United States.
Immune Deficiency Foundation · USNational Institutes of Health Clinical Center · USNational Institutes of Health · USUniversity of Turin · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Introduction: Mulibrey nanism (MUL) is a rare disorder caused by Methods: We present a case of MUL with progressive lymphopenia and review similar cases from the literature. Results: Our patient presented with prenatal onset growth restriction, characteristic dysmorphic features, and Wilms' tumor. She developed progressive lymphopenia starting at 10 years of age, leading to the initiation of intravenous immunoglobulin (IVIG) replacement therapy and infection prophylaxis. Genetic analysis detected a likely pathogenic variant on the maternal allele and copy number loss on the paternal allele in Discussion: The immunological profile of MUL patients reported so far shares similarities with that described in protein-losing enteropathy secondary to CHF in Fontan circulation and primary intestinal lymphangiectasia. These similarities include hypogammaglobulinemia, significant T-cell deficiency with decreased CD4+ and CD8+ counts, altered CD4+/CD8+ ratios, and significantly modified CD4+ and CD8+ T-cell phenotypes toward effector and terminal differentiated T cells, accompanied by a loss of naïve CD45RA+ T lymphocytes. In MUL, CHF is a cardinal feature, occurring in a significant proportion of patients and influencing prognosis. Signs of CHF or constrictive pericarditis have been evident in the case reported here and in all cases of MUL with documented immune dysfunction reported so far. These observations raise intriguing connections between these conditions. However, further investigation is warranted to in-depth define the immunological defect, providing valuable insights into the pathophysiology and treatment strategies for this condition.

Indexed as

AgammaglobulinemiaHeart FailureKidney NeoplasmsLymphopeniaMulibrey NanismWilms TumorFemaleHumansImmunoglobulins, IntravenousMutationNuclear ProteinsTripartite Motif ProteinsUbiquitin-Protein LigasesImmunoglobulins, IntravenousNuclear ProteinsTRIM37 protein, humanTripartite Motif ProteinsUbiquitin-Protein Ligasescase reportCD4+ lymphopeniahypogammaglobulinemiaMulibreypericardial constriction

Identifiers

PMID38116000
PMCPMC10728670
OpenAlexW4389344607

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.